Adaptive Biotechnologies (ADPT) Projected to Post Quarterly Earnings on Thursday

Adaptive Biotechnologies (NASDAQ:ADPT) is anticipated to release its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect Adaptive Biotechnologies to post earnings of ($0.19) per share and revenue of $59.3830 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $93.97 million during the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company’s quarterly revenue was up 102.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.22) EPS. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $18.39 on Tuesday. Adaptive Biotechnologies has a 1 year low of $6.26 and a 1 year high of $20.76. The company has a market cap of $2.81 billion, a P/E ratio of -34.05 and a beta of 2.18. The stock’s fifty day moving average price is $17.25 and its 200-day moving average price is $15.08.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 7th. Morgan Stanley initiated coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective for the company. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Guggenheim raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.22.

Insider Activity at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 124,998 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $15.59, for a total value of $1,948,718.82. Following the completion of the transaction, the chief executive officer owned 2,584,243 shares of the company’s stock, valued at approximately $40,288,348.37. This represents a 4.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Francis Lo sold 79,590 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $17.73, for a total value of $1,411,130.70. Following the completion of the sale, the insider owned 315,978 shares of the company’s stock, valued at $5,602,289.94. The trade was a 20.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,442,530 shares of company stock worth $24,610,748 in the last 90 days. Insiders own 6.40% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after buying an additional 933 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after acquiring an additional 1,119 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after acquiring an additional 2,914 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Adaptive Biotechnologies by 2.7% in the 3rd quarter. Alliancebernstein L.P. now owns 156,290 shares of the company’s stock valued at $2,338,000 after acquiring an additional 4,100 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its stake in Adaptive Biotechnologies by 17.6% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 30,469 shares of the company’s stock worth $456,000 after purchasing an additional 4,552 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.